Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $4.51B
• Dividend Yield: N/A
• Average Volume (3M): 2.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: -81.10%
• EPS Growth: -99.21%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.37
• Shares Outstanding: 95,985,310
• 10 Day Avg. Volume: 3,025,942
• 30 Day Avg. Volume: 2,067,433
• PEG Ratio: -0.17
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 1343.50
• P/FCF Ratio: -13.63
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 1.74K
• Enterprise Value/Gross Profit: -20.28
• Enterprise Value/Ebitda: -7.34
• 1Y Price Target: $70.57
• Price Target Upside: 50.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): -4.88
• Revenue Forecast (FY): $48.95M

• Rating: 47 Neutral
• Price Target: $48.00 ▲(2.24% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by weak and inconsistent operating performance (revenue collapse, sustained losses, and cash burn) and bearish technicals (below key moving averages with negative momentum). A solid, low-leverage balance sheet and recent capital raising improve liquidity, but they do not fully offset the current lack of financial consistency and negative momentum; valuation support is also limited due to ongoing losses and no dividend.

Positive Factors

Low leverage / strong balance sheet

Modest debt-to-equity and stable assets/equity provide durable financial flexibility. This reduces near-term refinancing risk and supports multi-quarter R&D and trial spend, allowing the company to advance multiple programs before needing material commercial revenue or dilutive financings.

Completed $600M convertible notes offering

The sizable convertible notes issuance materially strengthens liquidity and extends the operational runway. With roughly $585M net proceeds earmarked for general corporate purposes, the company can fund clinical programs and partnerships across 2–6 months without immediate revenue, lowering short-term funding pressure.

Broad pipeline progress with positive early data

Multiple positive early clinical readouts and IND-enabling work across cardiovascular, metabolic, hematology and cell therapy expand the company's addressable markets. Clinical momentum and a major pharma collaboration (Eli Lilly) increase the probability of future milestone revenue and de-risk single-program dependency over time.

Negative Factors

Highly episodic revenue

Dependence on irregular collaboration payments and milestone events creates large revenue swings and weak predictability. A ~90% revenue drop in 2025 underscores that near-term cash inflows are lumpy, making multi-quarter budgeting and sustained R&D investment planning fragile until commercial products emerge.

Persistent cash burn / negative free cash flow

Repeated negative operating and free cash flows signal structural funding needs until commercialization. Even with 2025 improvement, ongoing cash burn necessitates access to capital markets or partnerships, which can constrain strategic optionality and increase dilution or financing costs over the coming months.

Deep ongoing losses and weak margins

Sustained net losses and negative gross margins reduce retained capital and limit reinvestment capacity absent external funding. Continued unprofitability over multiple years raises the risk that operational setbacks or trial delays will erode equity or force more dilutive financings before products generate stable revenue.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics makes money primarily through (1) collaboration and partnership revenue and (2) any product-related revenue if/when its therapies are commercialized. Collaboration revenue has historically been a key source, including payments such as upfront fees, research funding, and milestone payments tied to development, regulatory, or commercial events, as well as potential royalties or profit-sharing on partnered products. A major partnership has been with Vertex Pharmaceuticals, under which the companies collaborated on a CRISPR-based therapy for certain hemoglobinopathies; the economics of such arrangements typically include shared development responsibilities and downstream economics (e.g., profit share and/or milestones and royalties) based on the agreement terms. Beyond partnerships, the company may generate revenue from licensing its intellectual property and technology to third parties, which can include license fees and milestones. Because Crispr Therapeutics is a development-stage biotech, its ability to generate significant recurring revenue depends heavily on the progress, approval, and commercialization of its therapeutic candidates, as well as the timing and achievement of partnership milestones.

Crispr Therapeutics AG Financial Statement Overview

Summary

Financials are mixed and volatile: revenue is highly episodic and collapsed in 2025 (~90% decline vs. 2024), with deep ongoing losses and negative margins. Cash flow remains a key weakness with continued operating/free-cash-flow burn despite some improvement in 2025. The main offset is a relatively strong balance sheet with modest leverage (low debt-to-equity) that supports near-term flexibility.

Income Statement

Revenue has been highly volatile and recently collapsed (2025 revenue down ~90% vs. 2024), highlighting dependence on irregular collaboration or milestone income. Profitability is weak: the company is deeply loss-making in 2022–2025 with very negative gross and net margins in the latest year, and operating losses expanded again in 2025. A key positive is that 2021 showed the model can be profitable when revenue events occur, but the lack of consistency and the sharp 2025 deterioration weigh heavily on the score.

Balance Sheet

The balance sheet is a relative strength: leverage is modest with debt-to-equity staying low (~0.09–0.13 across the period) and equity remains large versus total debt, providing financial flexibility. Total assets and equity have been broadly stable, suggesting the company has been able to fund operations without heavy debt. The main weakness is persistent negative returns on equity in most years (except 2021), reflecting ongoing losses that can erode capital over time if not reversed.

Cash Flow

Cash generation is a concern: operating cash flow and free cash flow are negative in most years (2020, 2022–2025), indicating ongoing cash burn. While 2025 free cash flow improved versus 2024 (positive growth rate) and free cash flow has generally tracked net income (losses), the business still requires funding support until operations turn sustainably cash-positive. The standout strength is 2021, when operating and free cash flow were strongly positive, but that performance has not been sustained.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.51M	35.00M	370.00M	436.00K	913.08M
Gross Profit	-229.45M	-75.25M	239.75M	-109.81M	811.90M
EBITDA	-548.84M	-447.31M	-202.70M	-648.99M	391.48M
Net Income	-581.60M	-366.25M	-153.61M	-650.17M	377.66M
Balance Sheet
Total Assets	2.27B	2.24B	2.23B	2.24B	2.75B
Cash, Cash Equivalents and Short-Term Investments	1.98B	1.90B	1.69B	1.82B	2.38B
Total Debt	394.91M	223.69M	238.63M	244.02M	225.03M
Total Liabilities	343.43M	309.95M	346.77M	367.58M	352.42M
Stockholders Equity	1.92B	1.93B	1.88B	1.88B	2.40B
Cash Flow
Free Cash Flow	-345.93M	-144.68M	-269.85M	-532.93M	457.27M
Operating Cash Flow	-345.01M	-142.77M	-260.38M	-495.74M	538.97M
Investing Cash Flow	-31.80M	-280.48M	374.65M	-258.65M	-1.04B
Financing Cash Flow	426.03M	331.98M	62.66M	38.59M	250.94M

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Negative. The current price of 46.95 is below the 20-day moving average (MA) of 54.31, below the 50-day MA of 53.57, and below the 200-day MA of 55.87, indicating a bearish trend. The MACD of -1.67 indicates Positive momentum. The RSI at 37.78 is Neutral, neither overbought nor oversold. The STOCH value of 9.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KYMR	64 Neutral	$6.50B	-21.09	-29.08%	―	-50.05%	-54.47%
NTLA	56 Neutral	$1.55B	-2.54	-56.63%	―	33.52%	21.66%
APLS	56 Neutral	$2.30B	141.40	8.20%	―	42.11%	―
BEAM	54 Neutral	$2.56B	-34.27	-7.31%	―	-84.07%	-157.71%
LEGN	52 Neutral	$3.30B	-6.73	-29.22%	―	74.91%	31.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRSP	47 Neutral	$4.51B	-8.11	-31.53%	―	-81.10%	-99.21%

Crispr Therapeutics AG Corporate Events

Crispr Therapeutics Completes $600 Million Convertible Notes Offering

On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offering of Convertible Senior Notes due 2031, including the full exercise of a $50 million option, with an effective coupon of 1.125% that was increased to 1.7308% to offset anticipated Swiss withholding tax for ineligible holders. The company received net proceeds of approximately $585.2 million, which it plans to use for general corporate purposes, strengthening its liquidity to support ongoing operations and strategic initiatives.

The notes are senior unsecured obligations maturing on March 1, 2031, carry semiannual interest payments starting September 1, 2026, and are convertible into common shares at an initial rate implying a roughly 45% premium to the March 10, 2026 Nasdaq share price. The indenture sets detailed terms on conversion adjustments, optional redemption after March 6, 2029, fundamental change repurchase rights, and customary covenants and events of default, shaping investor protections and the company’s future capital structure flexibility.

The most recent analyst rating on (CRSP) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million

On March 10, 2026, CRISPR Therapeutics AG announced plans to privately offer $350 million of convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $52.5 million. The notes will be senior unsecured obligations paying semiannual interest, maturing March 1, 2031, and convertible into the company’s common shares, with proceeds earmarked for general corporate purposes.

On March 11, 2026, the company disclosed that investor demand allowed it to upsize the planned convertible notes issuance to $550 million in aggregate principal amount. The successful pricing and expansion of the offering underscore CRISPR Therapeutics’ ability to tap capital markets to support its growing gene-editing franchise and may strengthen its financial flexibility as it advances commercial and pipeline programs in a competitive biotech landscape.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies

On January 12, 2026, CRISPR Therapeutics issued an update on its pipeline, underscoring progress across in vivo gene editing, cell therapy and regenerative medicine programs. In 2025, the company reported positive Phase 1 data for CTX310, showing deep and durable reductions in triglycerides and LDL cholesterol after a single IV dose with a favorable safety profile, and has moved the ANGPTL3-targeting therapy into Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia. CTX320, targeting LPA, has yielded up to 73% reductions in the dose-escalation phase, while next-generation LPA candidate CTX321, designed with a more potent guide RNA and the same LNP platform, is in IND/CTA-enabling studies alongside CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency, reflecting a broadening cardiovascular and metabolic portfolio. The company also highlighted progress for its CAR-T candidate zugocabtagene geleucel (zugo-cel) in autoimmune diseases and B-cell malignancies, with early systemic lupus erythematosus data showing sustained drug-free clinical remission and B-cell depletion in heavily pretreated patients, and an expanded oncology strategy via a collaboration with Eli Lilly to test zugo-cel with pirtobrutinib in aggressive B-cell lymphomas. In regenerative medicine, CRISPR Therapeutics reported promising 12‑month C-peptide data from diabetes candidate CTX211 that are guiding a shift toward next-generation hypoimmune cell therapy CTX213, which has shown strong preclinical efficacy and is being advanced toward clinical testing, signaling the company’s intent to consolidate its position as a leading player in gene-edited therapies across multiple high-need disease areas.

The most recent analyst rating on (CRSP) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.